Researchers have unveiled a novel approach to treating glioblastoma, one of the deadliest forms of brain cancer, using a specialized type of immune cell that can seek out and destroy tumors. The findings, presented at a major international pharmacology conference in Melbourne, offer a potential new path for patients who currently face limited treatment options.
Glioblastoma is notoriously aggressive, with tumors often returning after surgery, radiation, and chemotherapy. The experimental therapy harnesses gamma delta (γδ) T cells, a unique subset of immune cells that can recognize and attack cancer cells without requiring the standard immune-matching process needed by other cell therapies. In preclinical models, researchers delivered these specially expanded cells directly to the tumor site and observed potent and efficient destruction of brain cancer cells, according to data presented at the 2026 World Congress of Basic and Clinical Pharmacology.
The research is the result of a collaboration between SL Science, Taipei Medical University, JY BioMed, and HeXun Biosciences. The team focused on overcoming tumor immune evasion, a key reason glioblastoma resists existing treatments. By bypassing the cancer’s defenses, the gamma delta T cell approach could represent a significant shift in how solid brain tumors are targeted.
While the data come from preclinical studies, researchers are hopeful about the therapy’s potential for broader applications. SL Science is also exploring the use of gamma delta T cells against other solid tumors, including pancreatic cancer. The next steps will involve moving toward clinical trials to test the therapy in human patients, a process that could take several years. For now, the findings add to a growing body of evidence that immune cell therapies may one day offer a powerful weapon against cancers that have long defied treatment.